Novo Taps Veteran as CEO to Tackle Unprecedented Competition
- Joergensen joined Danish drugmaker as economist 25 years ago
- Novo under pressure from rival drugs in its largest market
This article is for subscribers only.
The man appointed to succeed Lars Rebien Soerensen as Novo Nordisk A/S’s chief executive officer says to expect continuity, but a challenging diabetes market may force him to diverge from Soerensen’s time-tested path.
Lars Fruergaard Joergensen is inheriting a tough assignment: steer the world’s largest insulin maker through intensifying pricing pressure in its biggest market, tackling what the 93-year-old Danish drugmaker has called unprecedented levels of competition.